Kothari Atul, Caradine Kari D, Rico Crescencio Juan Carlos, Sasapu Appalanaidu, Veeraputhiran Muthu K, Jethava Yogesh, Burgess Mary J
Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12747. Epub 2017 Sep 4.
We present the case of a young man with acute lymphoblastic leukemia who developed cytomegalovirus (CMV) appendicitis after receiving alemtuzumab for acute refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT). CMV appendicitis is a rare complication; and we are reporting the first case to our knowledge of CMV appendicitis following HSCT. Our case highlights the importance of recognition of CMV viral reactivation following the use of alemtuzumab. Using a preemptive strategy of checking CMV PCR, with initiation of early effective treatment on detection of CMV replication, may be appropriate following use of alemtuzumab in hematologic malignancies in patients after HSCT.
我们报告了一例年轻男性急性淋巴细胞白血病患者的病例，该患者在接受异基因造血干细胞移植（HSCT）后因急性难治性移植物抗宿主病接受阿仑单抗治疗后发生了巨细胞病毒（CMV）阑尾炎。CMV阑尾炎是一种罕见的并发症；据我们所知，我们报告了首例HSCT后发生CMV阑尾炎的病例。我们的病例强调了认识使用阿仑单抗后CMV病毒重新激活的重要性。在HSCT后的血液系统恶性肿瘤患者中使用阿仑单抗后，采用预先检查CMV PCR的策略，并在检测到CMV复制时启动早期有效治疗，可能是合适的。
